Special Issue "The Interleukin-6 Family in Disease Pathogenesis and Therapy"

A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: closed (30 April 2019)

Special Issue Editors

Guest Editor
Prof. Steven E. Mutsaers

University of Western Australia Faculty of Medicine and Dentistry, Centre for Cell Therapy and Regenerative Medicine, Perth, Australia
Website | E-Mail
Interests: Pulmonary fibrosis; mesothelial cell biology; malignant mesothelioma; post-operative adhesions; disease pathogenesis; cell signalling; animal models of disease
Guest Editor
Prof. Cecilia M. Prêle

Institute for Respiratory Health and University of Western Australia, Perth, Australia
Website | E-Mail
Interests: Pulmonary fibrosis; cell signalling; matrix regulation; malignant mesothelioma; immune regulation

Special Issue Information

Dear Colleagues,

The IL-6 family is a group of closely related pleiotropic cytokines produced by a variety of cells in response to inflammatory stimuli. They are related in structure and function and include IL-6, IL-11, leukemia inhibitory factor (LIF), Oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1), cardiotrophin like cytokine (CLC), IL-27, IL-31, and neuropoietin. The actions of these cytokines are mediated through specific cell surface receptors and the shared signal transducing subunit, gp130. Subsequent signalling is mediated through a tight reciprocal regulation of either ERK-MAPK or JAK-STAT pathways, critical for the generation of physiological responses to IL6-family cytokines. Conversely, disturbance of this finely orchestrated signalling, leads to pathological responses. The IL-6 family stimulates the inflammatory and autoimmune processes in many diseases. Hence, there is a strong interest in developing agents against these molecules or their signalling pathways to treat disease. Articles (original and reviews) are being sought for a Special Issue highlighting the importance of the IL-6 family of cytokines in both health and disease and novel approaches to modulate their function.

Prof. Steven E. Mutsaers
Prof. Cecilia M. Prêle
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • IL-6 family cytokines
  • disease pathogenesis
  • signalling pathways
  • STAT3, MAPK
  • gp130
  • inflammation
  • biomarker
  • therapeutics
  • fibrosis
  • cancer
  • autoimmune disease
  • arthritis
  • neurological disease
  • asthma

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview
Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease
Biomedicines 2019, 7(1), 19; https://doi.org/10.3390/biomedicines7010019
Received: 22 February 2019 / Revised: 8 March 2019 / Accepted: 10 March 2019 / Published: 13 March 2019
PDF Full-text (1209 KB) | HTML Full-text | XML Full-text
Abstract
Healthy kidneys are important for the efficient regulation of metabolism. However, there is an ever increasing population of patients suffering from both acute and chronic kidney diseases that disrupt this homeostasis. This review will explore the emerging roles that interleukin 6 (IL-6) cytokine [...] Read more.
Healthy kidneys are important for the efficient regulation of metabolism. However, there is an ever increasing population of patients suffering from both acute and chronic kidney diseases that disrupt this homeostasis. This review will explore the emerging roles that interleukin 6 (IL-6) cytokine family members play in the pathogenesis of kidney disease. The IL-6 family of cytokines are involved in a diverse range of physiological functions. In relation to kidney disease, their involvement is no less diverse. Evidence from both preclinical and clinical sources show that IL-6 cytokine family members can play either a deleterious or protective role in response to kidney disease. This appears to be dependent on the type of kidney disease in question or the specific cytokine. Current attempts to use or target IL-6 cytokine family members as therapies of kidney diseases will be highlighted throughout this review. Finally, the involvement of IL-6 cytokine family members in kidney disease will be presented in the context of three regularly overlapping conditions: obesity, hypertension and diabetes. Full article
(This article belongs to the Special Issue The Interleukin-6 Family in Disease Pathogenesis and Therapy)
Figures

Graphical abstract

Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top